# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committe...
Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 vaccine.
- Bloomberg
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration...
Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $178 to $139.
Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $155 to $125.
- Bloomberg
10 worst performing large-cap stocks last week: RTO, ALLY, MRNA, HUM, TSN, BEKE, ADBE, RYAAY, JPM, DVN. Consider impact on your...
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight ne...